Page 47 - Solid Tumors News Today

Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy Safety profile for the

Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating

Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME)

Tislelizumab is now approved for eight indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative

PALM BEACH, Fla., April 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patients T cells which is a type of immune system...

Stanford University engineers created a new delivery method that may enhance CAR T-cell therapy by targeting solid tumors such as breast cancer.

Press release content from PR Newswire. The AP news staff was not involved in its creation.

BNT211 combines two innovative approaches in one regimen, an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a...

Adding atezolizumab to capecitabine and bevacizumab did not provide a clinically meaningful benefit for patients with refractory mCRC.